This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Arena Pharma's Weight-Loss Pill Has Few Fans in Japan

Sakal forecasts $400 million in U.S. sales of Belviq in 2018.

Citi's Hidemaru Yamaguchi:

"We expect a 2013 launch for Belviq, with sales of $25.17 million in FY3/13, $125.86 million in FY3/14, $377.57 million in FY3/15, $566.36 million in FY3/16, and $623 million in FY3/17."

Barclays' Atsushi Seki:

"We revise our forecasts for Eisai to factor in sales of the obesity drug Belviq. We maintain our 2-EW rating on a peer comparison and expect investors to now focus on the drug's pricing, insurance coverage, and competition. This is not a high-margin drug for Eisai; we think gross margin could range from 30–50% depending on sales. We also expect Eisai to shoulder 90% of the costs for an upcoming clinical testing of the drug’s long-term safety and accordingly raise our forecast for R&D spending."

Lastly, the most optimistic Belviq outlook comes from Goldman Sachs' Steve Chesney:

"In our view, FDA approval without the need for additional pre-approval trials is a positive for Eisai. Approval came with some caveats, however, including that dosing should be stopped if 5% weight loss is not achieved within 12 weeks. Based upon the Belviq clinical data (58% of patients fail to achieve 5% weight loss by week 12) and the commercial experience of other weight loss drugs with similar efficacy, we believe lack of efficacy will significantly limit uptake for Belviq… Although we forecast $1.1bn billion in Belviq sales, contributing 13% to our FY3/17 top line, given the terms of the in-licensing deal (avg. 34% of sales to purchase from ARNA and additional $1.2bn purchase price adjustments on first $2.5bn of sales) we forecast 39% average GP margin, well below Eisai’s FY3/12 consolidated GP margin of 73%."

The consensus view from Japanese analysts seems to be that Eisai is getting a raw deal in its partnership with Arena, suggesting (without saying explicitly) tht perhaps Eisai needs to buy Arena to make Belviq profitable. But with growth slowing due to the loss of patent exclusivity for the Alzheimer's drug Aricept and the setbacks with its breast cancer drug Halaven, does Eisai have the financial resources necessary to make a run at Arena?

--Written by Adam Feuerstein in Boston.



>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Follow TheStreet on Twitter and become a fan on Facebook.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
ARNA $4.33 0.00%
OREX $7.54 0.00%
VVUS $2.57 0.00%
AAPL $123.25 0.00%
FB $83.30 0.00%

Markets

DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs